Land: Verenigde Staten
Taal: Engels
Bron: NLM (National Library of Medicine)
OLMESARTAN MEDOXOMIL (UNII: 6M97XTV3HD) (OLMESARTAN - UNII:8W1IQP3U10), HYDROCHLOROTHIAZIDE (UNII: 0J48LPH2TH) (HYDROCHLOROTHIAZIDE - UNII:0J48LPH2TH)
Torrent Pharmaceuticals Limited
OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL 20 mg
ORAL
PRESCRIPTION DRUG
Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2)] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals
20 mg/12.5 mg - Yellow to light orange colored, round, biconvex, film coated tablets, debossed with "1251" on one side and plain on the other side. Each tablet contains 20 mg of olmesartan medoxomil, USP and 12.5 mg of hydrochlorothiazide, USP. Bottles of 30 NDC 13668-251-30 Bottles of 90 NDC 13668-251-90 Bottles of 1000 NDC 13668-251-01 40 mg/12.5 mg - Yellowish pink to pink colored, oval shaped, biconvex, film coated tablets, debossed with "1252" on one side and plain on the other side. Each tablet contains 40 mg of olmesartan medoxomil, USP and 12.5 mg of hydrochlorothiazide, USP. Bottles of 30 NDC 13668-252-30 Bottles of 90 NDC 13668-252-90 Bottles of 1000 NDC 13668-252-01 40 mg/25 mg - Pink to peach colored, oval shaped, biconvex, film coated tablets, debossed with "1253" on one side and plain on the other side. Each tablet contains 40 mg of olmesartan medoxomil, USP and 25 mg of hydrochlorothiazide, USP. Bottles of 30 NDC 13668-253-30 Bottles of 90 NDC 13668-253-90 Bottles of 1000 NDC 13668-253-01 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE- OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 20/12.5 TABLET TORRENT PHARMACEUTICALS LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE TABLETS. OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2003 WARNING: FETAL TOXICITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ WHEN PREGNANCY IS DETECTED, DISCONTINUE OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE TABLETS AS SOON AS POSSIBLE (5.1). DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE INJURY AND DEATH TO THE DEVELOPING FETUS (5.1). INDICATIONS AND USAGE Olmesartan medoxomil and hydrochlorothiazide tablets are a combination of olmesartan, an angiotensin II receptor blocker and hydrochlorothiazide, a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1) DOSAGE AND ADMINISTRATION Recommended starting dose in patients not adequately controlled with olmesartan monotherapy, 40/12.5 mg (2) Recommended starting dose in patients not adequately controlled with hydrochlorothiazide monotherapy, 20/12.5 mg (2) Adjust dose after 2 to 4 weeks, as needed, to a maximum of 40 mg / 25 mg olmesartan / hydrochlorothiazide (2) DOSAGE FORMS AND STRENGTHS Tablets: (olmesartan medoxomil and hydrochlorothiazide) 20/12.5 mg; 40/12.5 mg; 40/25 mg (3) CONTRAINDICATIONS Hypersensitivity to any component of olmesartan medoxomil and hydrochlorothiazide tablets (4) Anuria (4) Do not co-administer aliskiren with olmesartan medoxomil and hydrochlorothiazide tablets in patients with diabetes. (4) WARNINGS AND PRECAUTIONS Hypotension: Correct volume-depletion prior to administration. (5.2) Lees het volledige document